Magnitude and associated factors of anemia among AZT based HAART experienced adult HIV patients at University of Gondar Comprehensive Specialized Referral Hospital, Northwest, Ethiopia, 2019: a retrospective cohort study.
Anemia
Associated factors
HIV/AIDS
Hemoglobin
Zidovudine
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
03
04
2020
accepted:
20
09
2021
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
1
10
2021
Statut:
epublish
Résumé
Anemia is the most common hematologic abnormalities in AIDS patients usually associated with disease progression and poor clinical outcomes. Zidovudine (AZT), which is one of the nucleoside reverse transcriptase inhibitor drug families of the first line antiretroviral therapy regimen for HIV/AIDS patients, causes anemia due to early long-term of higher-dose therapy. This study was aimed to assess the magnitude and associated factors of anemia among AZT containing HAART experienced adult HIV/ADIS patients at University of Gondar Comprehensive Specialized Referral Hospital, northwest, Ethiopia, 2019. A retrospective cohort study was conducted among a total of 320 adult AZT based HAART experienced HIV/AIDS patients from January 2016 to December 2018. Systematic random sampling technique was used to select the patients' charts. All required data for this study were extracted from patients' medical charts. Data were coded, cleared and entered into Epi Info version 3.5.3, and transformed to SPSS version 20 for analysis. Descriptive statistics, bivariable and multivariable logistic regression models were fitted to identify associated factors of anemia and P-value < 0.05 was considered as statistically significance. A total of 320 adult AZT based HAART experienced HIV/AIDS patients' charts were assessed. Of the total patients, 198 (61.9%) were females and 133 (41.6%) were within the age range of 35-45 years. More than half, 237(76.9%) of the patients were from the urban area and 186 (58.1%) were on WHO clinical stage III at the baseline. The prevalence of anemia was 50% (95% CI 44.7-55.0%), 44.1% (95% CI 38.4-50.0%), 35.6% (95% CI 30.3-40.6%), 40% (95% CI 34.4-45.6%), 40.6% (95% CI 35.0-46.3) and 39.1% (95% CI 33.4-44.1%) at baseline, 6 months, 12 months, 18 months, 24 months and 30 months of follow-up period, respectively. The overall prevalence of anemia was 41.6%. Anemia had significant association with WHO clinical stage and base line Hgb values. A significant number of participants were anemic in this study. WHO clinical stage and baseline Hgb value were the contributing factors for anemia among these patients. Therefore, anemia needs an immediate intervention on associated factor to improve the anemic status and living condition of HIV patient.
Sections du résumé
BACKGROUND
BACKGROUND
Anemia is the most common hematologic abnormalities in AIDS patients usually associated with disease progression and poor clinical outcomes. Zidovudine (AZT), which is one of the nucleoside reverse transcriptase inhibitor drug families of the first line antiretroviral therapy regimen for HIV/AIDS patients, causes anemia due to early long-term of higher-dose therapy. This study was aimed to assess the magnitude and associated factors of anemia among AZT containing HAART experienced adult HIV/ADIS patients at University of Gondar Comprehensive Specialized Referral Hospital, northwest, Ethiopia, 2019.
METHODS
METHODS
A retrospective cohort study was conducted among a total of 320 adult AZT based HAART experienced HIV/AIDS patients from January 2016 to December 2018. Systematic random sampling technique was used to select the patients' charts. All required data for this study were extracted from patients' medical charts. Data were coded, cleared and entered into Epi Info version 3.5.3, and transformed to SPSS version 20 for analysis. Descriptive statistics, bivariable and multivariable logistic regression models were fitted to identify associated factors of anemia and P-value < 0.05 was considered as statistically significance.
RESULTS
RESULTS
A total of 320 adult AZT based HAART experienced HIV/AIDS patients' charts were assessed. Of the total patients, 198 (61.9%) were females and 133 (41.6%) were within the age range of 35-45 years. More than half, 237(76.9%) of the patients were from the urban area and 186 (58.1%) were on WHO clinical stage III at the baseline. The prevalence of anemia was 50% (95% CI 44.7-55.0%), 44.1% (95% CI 38.4-50.0%), 35.6% (95% CI 30.3-40.6%), 40% (95% CI 34.4-45.6%), 40.6% (95% CI 35.0-46.3) and 39.1% (95% CI 33.4-44.1%) at baseline, 6 months, 12 months, 18 months, 24 months and 30 months of follow-up period, respectively. The overall prevalence of anemia was 41.6%. Anemia had significant association with WHO clinical stage and base line Hgb values.
CONCLUSIONS
CONCLUSIONS
A significant number of participants were anemic in this study. WHO clinical stage and baseline Hgb value were the contributing factors for anemia among these patients. Therefore, anemia needs an immediate intervention on associated factor to improve the anemic status and living condition of HIV patient.
Identifiants
pubmed: 34583644
doi: 10.1186/s12879-021-06712-5
pii: 10.1186/s12879-021-06712-5
pmc: PMC8480035
doi:
Substances chimiques
Zidovudine
4B9XT59T7S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1016Informations de copyright
© 2021. The Author(s).
Références
Public Health Nutr. 2009 Apr;12(4):444-54
pubmed: 18498676
Arch Intern Med. 1989 Sep;149(9):2039-41
pubmed: 2774781
Med Clin North Am. 1997 Mar;81(2):449-70
pubmed: 9093237
AIDS. 1999 May 28;13(8):943-50
pubmed: 10371175
J Assoc Physicians India. 2013 Sep;61(9):673-5
pubmed: 24772715
Am J Hematol. 1992 Jun;40(2):103-9
pubmed: 1585907
Indian J Med Res. 2010 Oct;132:386-9
pubmed: 20966515
Eur J Haematol. 1989 Apr;42(4):339-43
pubmed: 2721658
Semin Hematol. 1988 Jul;25(3):208-18
pubmed: 3043675
HIV AIDS (Auckl). 2017 Feb 14;9:25-30
pubmed: 28243151
PLoS One. 2013;8(3):e60206
pubmed: 23555926
N Am J Med Sci. 2011 Dec;3(12):548-51
pubmed: 22363076
J Int Assoc Physicians AIDS Care (Chic). 2009 Mar-Apr;8(2):128-38
pubmed: 19270152
Ethiop J Health Sci. 2017 Feb;27(Suppl 1):1-2
pubmed: 28465648
BMC Hematol. 2014 Mar 25;14(1):8
pubmed: 24666771
J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):428-37
pubmed: 22433846
BMC Hematol. 2015 Apr 30;15:6
pubmed: 26045966
J Infect Dis. 2002 Jan 15;185(2):178-87
pubmed: 11807691
Lancet. 1986 Mar 15;1(8481):575-80
pubmed: 2869302
Br J Haematol. 1991 Sep;79(1):127
pubmed: 1911374
Baillieres Clin Endocrinol Metab. 1998 Oct;12(3):379-90
pubmed: 10332560
Clin Infect Dis. 2004 May 15;38(10):1454-63
pubmed: 15156485
Rev Infect Dis. 1990 Sep-Oct;12(5):931-7
pubmed: 2237134
Baillieres Best Pract Res Clin Haematol. 2000 Jun;13(2):215-30
pubmed: 10942622
BMC Hematol. 2013 Aug 09;13(1):8
pubmed: 24238076
PLoS One. 2013;8(2):e57223
pubmed: 23468942
EJIFCC. 2018 Apr 30;29(1):36-47
pubmed: 29765285
Indian J Hematol Blood Transfus. 2015 Jun;31(2):247-50
pubmed: 25825566
Blood. 1998 Jan 1;91(1):301-8
pubmed: 9414298
Am J Med. 2004 Apr 5;116 Suppl 7A:27S-43S
pubmed: 15050884
Braz J Infect Dis. 2020 Jan - Feb;24(1):65-72
pubmed: 31835018
J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):28-35
pubmed: 11176266
BMC Res Notes. 2010 Aug 20;3:230
pubmed: 20727136